

David Price - Conflict of Interest Information

10 November 2016 (see next page for COI as one paragraph)

Board Membership: Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals

Consultancy agreements: Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance

Grants and unrestricted funding for investigator-initiated studies

(conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva

Payment for lectures/speaking engagements: Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals

Payment for manuscript preparation: Mundipharma and Teva Pharmaceuticals

Payment for the development of educational materials: Mundipharma and Novartis

Payment for travel/accommodation/meeting expenses: Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals

Funding for patient enrolment or completion of research: Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva

Stock/stock options: AKL Ltd which produces phytopharmaceuticals;

Owns 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore

Peer reviewer for grant committees: Efficacy and Mechanism Evaluation programme, HTA, and Medical Research Council

Bolded COI categories for easier review when updating

Professor David Price has **board membership** with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Meda, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; **consultancy agreements** with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Meda, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; **grants and unrestricted funding for investigator-initiated studies** (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Meda, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Takeda, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva; **payment for lectures/speaking engagements** from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Meda, Merck, Mundipharma, Novartis, Pfizer, Skyepharma, Takeda, and Teva Pharmaceuticals; **payment for manuscript preparation** from Mundipharma and Teva Pharmaceuticals; **payment for the development of educational materials** from Mundipharma and Novartis; **payment for travel/accommodation/meeting expenses** from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; **funding for patient enrolment or completion of research** from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; **stock/stock options** from AKL Ltd which produces phytopharmaceuticals; **owns** 74% of the social enterprise Optimum Patient Care Ltd, UK and 74% of Observational and Pragmatic Research Institute Pte Ltd, Singapore; and is **peer reviewer for grant committees** of the Efficacy and Mechanism Evaluation programme, HTA, and Medical Research Council.